Lilly ‘Re-Balance’ Could Affect up to 100 Workers

Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now

This audio file is brought to you by

0:00

0:00

Loading audio file, please wait.

Speed
1.00

• 0.25
• 0.50
• 0.75
• 1.00
• 1.25
• 1.50
• 1.75
• 2.00

Eli Lilly and Co. (NYSE: LLY) says it will “re-balance” its tablet and capsule manufacturing network by shifting production among its sites in Indianapolis, Spain and Puerto Rico. The company confirms to Inside INdiana Business up to 100 workers at its Indianapolis operations could be affected by the moves over the next several years. Lilly says those employees will have opportunities to move to other positions in areas including insulin and biotechnology. The company says patent expirations are among the reasons for the move.

Late last year, Lilly said it would invest more than $700 million in insulin production operations in Indianapolis, Puerto Rico, France and China.

Lilly is pursuing a plan to re-balance drug product manufacturing activities for several solid oral dosage products, which are tablets and capsules, between its production sites in Indianapolis, Spain, and Puerto Rico. This is part of our ongoing efforts to align our capabilities with the needs of our portfolio, which includes growth in insulin and biotechnology-derived products together with patent expirations affecting solid oral dosage manufacturing.

As a result, across our dry-products manufacturing network, Lilly is going to implement a network realignment to rebalance various dry-product activities.

For Indy Dry, we will begin the transfer of some products to other dry-product sites. At the same time, there will be some necessary investments at Indy Dry for the next generation of our pipeline, as we will continue to partner with our development organization in advancing that pipeline.

This transition will take several years to implement. Employees affected by this plan will have opportunities to move elsewhere within manufacturing, such as our growing insulin and biotechnology areas. As previously announced, Lilly continues to advance insulin-related investments in Indianapolis totaling nearly half a billion dollars to expand insulin active ingredient and drug product manufacturing capacity.

Source: Eli Lilly and Co.